Human cancer is caused by multiple factors, such as genetic predisposition, chronic persistent inflammation, environmental factors, life style, and aging. Dysregulated proliferation, dysregulated adhesion, resistance to apoptosis, resistance to senescence, and resistance to anti-cancer drugs are features of cancer cells. Accumulation of multiple epigenetic changes and genetic alterations of cancer-associated genes during multi-stage carcinogenesis results in more malignant phenotypes. Post-genome science is characterized by omics data related to genome, transcriptome, proteome, metabolome, interactome, and epigenome as well as by high-throughput technology, such as whole-genome tiling oligonucleotide array, array CGH with 32,433 overlapping BAC clones, transcriptome microarray, mass spectrometry, tissue-based expression array, and cell-based transfection array. Benchtop oncology supplies Desktop oncology with large amounts of omics data produced by high-throughput technology. Desktop oncology establishes knowledge on cancer-related biomarkers, such as predisposition markers, diagnostic markers, prognostic markers, and therapeutic markers, by using bioinformatics and human intelligence of experts for data mining and text mining. Bedside oncology applies the knowledge established by Desktop oncology to determine therapeutics for cancer patients. Antibody drugs (Trastuzumab/Herceptin, Cetuximab/Erbitux, Bevacizumab/Avastin, et cetera), small molecule inhibitors for tyrosine kinases (Gefitinib/Iressa, Erlotinib/Tarceva, Imatinib/Gleevec, et cetera), conventional cytotoxic drugs, and anti-hormonal drugs are used for cancer chemotherapy. Biomarker monitoring contributes to therapeutic optional choice and drug dosage determination for cancer patients. Knowledge on biomarkers is feedforwarded from desktop to bedside in the translational research, and then biomarker monitoring is feedbacked from bedside to desktop in the reverse translational research. Desktop oncology is indispensable for cancer research in the post-genome era. Combination of genetic screening for cancer predisposition in the general population and precise selection of therapeutic options during cancer management could contribute to the realization of personalized prevention and to dramatically improve the prognosis of cancer patients in the future.
FearonE. R., VogelsteinB.A Genetic Model for Colorectal Tumori-genesis. Cell61, 759–767 (1990).
2.
SugimuraT., TeradaM., YokotaJ., HirohashiS., WakabayashiK.Multiple Genetic Alterations in Human Carcinogenesis. Environ. Health Perspect.98, 5–12 (1992).
3.
KatohM., TeradaM.Oncogenes and Tumor Suppressor Genes. In Gastric Cancer, pp. 196–208. Eds., NishiM.. Springer-verlag, Tokyo (1993).
4.
KatohM., KatohM.Pharmacogenomics on Gastric Cancer. Cancer Biol. Ther.3, 566–567 (2004).
5.
KatohM.WNT and FGF Gene Clusters. Int. J. Oncol.21, 1269–1273 (2002).
6.
Garciadiego-CazaresD., RosalesC., KatohM., Chimal-MonroyJ.Coordination of Chondrocyte Differentiation and Joint Formation by α5β1 Integrin in the Developing Appendicular Skeleton. Development131, 4735–4742 (2004).
7.
KatohY., KatohM.Hedgehog Signaling in Gastric Cancer. Cancer Biol. Ther.4, 1050–1054 (2005).
8.
KatohM.WNT2b: Comparative Integromics and Clinical Application. Int. J. Mol. Med.16, 1103–1108 (2005).
9.
SwainR. K., KatohM., MedinaA., SteinbeisserH.Xenopus Frizzled-4S, A Splicing Variant Of Xfz4, is a Context-dependent Activator and Inhibitor of Wnt/β-catenin Signaling. Cell Commun. Signal3, 12 (2005).
10.
KatohM.Regulation of WNT Signaling Molecules by Retinoic Acid During Neuronal Differentiation in NT2 Cells: Threshold Model of WNT Action. Int. J. Mol. Med.10, 683–687 (2002).
11.
KatohM., KatohM.Identification and Characterization of Human BCL9L Gene and Mouse Bc191 Gene In Silico. Int. J. Mol. Med.12, 643–649 (2003).
12.
KatohM.Paradignshift in Gene-finding Method: From Benchtop Approach to Desk-top Approach. Int. J. Mol. Med.10, 677–682 (2002).
MalkinD., LiF. P., StrongL. C.. Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms. Science250, 1233–1238 (1990).
15.
LeeW. H., BooksteinR., HongF.. Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence. Science235, 1394–1399 (1987).
16.
NishishoI., NakamuraY., MiyoshiY.Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients. Science253, 665–669 (1991).
17.
MikiY., SwensenJ., Shattuck-EidensD.A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science266, 66–71 (1994).
EngC., HampelH., de la ChapelleA.Genetic Testing for Cancer Predisposition. Annu. Rev. Med.52, 371–400 (2001).
20.
SoussiT., BeroudC.Assessing TP53 Status in Human Tumours to Evaluate Clinical Outcome. Nat. Rev. Cancer1, 233–240 (2001).
21.
ParsonnetJ., FriedmanG. D., VandersteenD. P.Helicobacter pylori Infection and the Risk of Gastric Carcinoma. N. Engl. J. Med.325, 1127–1131 (1991).
22.
BruixJ., BarreraJ. M., CalvetX.Prevalence of Antibodies to Hepatitis C Virus in Spanish Patients with Hepatocellular Carcinoma and Hepatic Cirrhosis. Lancet2, 1004–1006 (1989).
ZhaoX., LiC., PaezJ. G.An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays. Cancer Res.64, 3060–3071 (2004).
25.
BertoneP., StolcV., RoyceT. E.Global Identification of Human Transcribed Sequences with Genome Tiling Arrays. Science306, 2242–2246 (2004).
26.
KallioniemiO. P.Biochip Technologies in Cancer Research. Ann. Med.33, 142–147 (2001).
27.
DerisiJ., PenlandL., BrownP. O.Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer. Nat. Genet.14, 457–460 (1996).
28.
KhanJ., SimonR., BittnerM.Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays. Cancer Res.58, 5009–5013 (1998).
29.
KatohM., KatohM.CLDN23 Gene, Frequently Down-regulated in Intestinal-type Gastric Cancer, is a Novel Member of CLAUDIN Gene Family. Int. J. Mol. Med.11, 683–689 (2003).
30.
KatohM., KatohM.MGC29506 Gene, Frequently Down-regulated in Intestinal-type Gastric Cancer, Encodes Secreted-type Protein with Conserved Cysteine Residues. Int. J. Oncol.23, 235–241 (2003).
31.
KatohM., KatohM.IGSF11 Gene, Frequently Up-regulated in Intestinal-type Gastric Cancer, Encodes Adhesion Molecule Homologous to CXADR, FLJ22415 and ESAM. Int. J. Oncol.23, 525–531 (2003).
32.
SgroiD. C., TengS., RobinsonG.In Vivo Gene Expression Profile Analysis of Human Breast Cancer Progression. Cancer Res.59, 5656–5661 (1999).
33.
AlevizosI., MahadevappaM., ZhangX.Oral Cancer In Vivo Gene Expression Profiling Assisted by Laser Capture Microdissection and Microarray Analysis. Oncogene20, 6196–6204 (2001).
34.
HasegawaS., FurukawaY., LiM.Genome-wide Analysis of Gene Expression in Intestinal-type Gastric Cancers Using a Complementary DNA Microarray Representing 23, 040 Genes. Cancer Res.62, 7012–7017 (2002).
35.
KatohM., KatohM.MGC9753 Gene, Located Within PPP1R1B-STARD3-ERBB2-GRB7 Amplicon on Human Chromosome 17q12, Encodes Seven-transmembrane Receptor with Extracellular Six-cystein Domain. Int. J. Oncol.22, 1369–1374 (2003).
36.
KatohM., KatohM.Evolutionary Recombination Hotspot Around GSDML~GSDM Locus is Closely Linked to Oncogenomic Recombination Hotspot Around PPP1R1B~ERBB2~GRB7 Amplicon. Int. J. Oncol.24, 757–763 (2004).
37.
KatohM., KatohM.FLJ10261 Gene, Located Within the CCND1~MS1 Locus on Human Chromosome 11q13, Encodes Eight-transmembrane Protein Homologous To C12orf3, C11orf25, and Flj34272 Gene Products. Int. J. Oncol.22, 1375–1381 (2003).
38.
KatohM., KatohM.Evolutionary Conservation Of CCND1-ORAOV1-FGF19-FGF4 Locus from Zebrafish to Human. Int. J. Mol. Med.12, 45–50 (2003).
39.
PollackJ. R., SorlieT., PerouC. M.Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors. Proc. Natl. Acad. Sci. USA99, 12963–12968 (2002).
40.
HymanE., KauraniemiP., HautaniemiS.Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer. Cancer Res.62, 6240–6245 (2002).
41.
IshkanianA. S., MalloffC. A., WatsonS. K.A Tiling Resolution DNA Microarray with Complete Coverage of the Human Genome. Nat. Genet.36, 299–303 (2004).
42.
PetricoinE. F., ArdekaniA. M., HittB. A.Use of Proteomic Patterns in Serum to Identify Ovarian Cancer. Lancet359, 572–577 (2002).
43.
Yazidi-BelkouraI. E., AdriaenssensE., Vercoutter-EdouartA. S.Proteomics of Breast Cancer: Outcomes and Prospects. Technol. Cancer Res. Treat.1, 287–296 (2002).
44.
RostyC., GogginsM.Identification of Differentially Expressed Proteins in Pancreatic Cancer using a Global Proteomic Approach. Methods Mol. Med.103, 189–197 (2005).
45.
VlahouA., SchellhammerP. F., MendrinosS.Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine. Am. J. Pathol.158, 1491–502 (2001).
46.
Lyons-WeilerJ., PatelS., BhattacharyaS.A Classification-based Machine Learning Approach for the Analysis of Genome-wide Expression Data. Genome Res.13, 503–512 (2003).
47.
LiuE. T.Classification of Cancers by Expression Profiling. Curr. Opin. Genet. Dev.13, 97–103 (2003).
48.
LaurenP.The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-called Intestinal-type Carcinoma. Acta. Pathol. Microbiol. Scand.64, 31–49 (1965).
49.
KatohM.Trefoil Factors and Human Gastric Cancer. Int. J. Mol. Med.12, 3–9 (2003).
50.
SchenaM., HellerR. A., TheriaultT. P.Microarrays: Biotechnology's Discovery Platform for Functional Genomics. Trends Biotechnol.16, 301–306 (1998).
51.
ZweigerG.Knowledge Discovery in Gene-expression-microarray Data: Mining the Information Output of the Genome. Trends Biotechnol.17, 429–436 (1999).
52.
van't VeerL. J., DaiH., van de VijverM. J.Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer. Nature415, 530–536 (2002).
53.
van de VijverM. J., HeY. D., van't VeerL. J.A Gene-expression Signature as a Predictor of Survival in Breast Cancer. N. Engl. J. Med.347, 1999–2009 (2002).
54.
WellmannA., WollscheidV., LuH.Analysis of Microdis-sected Prostate Tissue with ProteinChip Arrays-A way to New Insights into Carcinogenesis and to Diagnostic Tools. Int. J. Mol. Med.9, 341–347 (2002).
55.
GharibT. G., ChenG., WangH.Proteomic Analysis of Cytokeratin Isoforms Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia4, 440–448 (2002).
56.
McDonaldS. L., EdingtonH. D., KirkwoodJ. M., BeckerD.Expression Analysis of Genes Identified by Molecular Profiling of VGP Melanomas and MGP Melanoma-positive Lymph Nodes. Cancer Biol. Ther.3, 110–120 (2004).
57.
CallagyG., PharoahP., ChinS. F.Identification and Validation of Prognostic Markers in Breast Cancer with the Complementary use of Array-CGH and Tissue Microarrays. J. Pathol.205, 388–396 (2005).
58.
MichielsS., KoscielnyS., HillC.Prediction of Cancer Outcome With Microarrays: A Multiple Random Validation Strategy. Lancet365, 488–492 (2005).
59.
KiharaC., TsunodaT., TanakaT.Prediction of Sensitivity of Esophageal Tumors to Adjuvant Chemotherapy by cDNA Microarray Analysis of Gene-expression Profiles. Cancer Res.61, 6474–6479 (2001).
60.
WongY. F., SelvanayagamZ. E., WeiN.Expression Genomics of Cervical Cancer: Molecular Classification and Prediction of Radiotherapy Response by DNA Microarray. Clin. Cancer Res.9, 5486–5492 (2003).
61.
ReichertJ. M., RosensweigC. J., FadenL. B., DewitzM. C.Monoclonal Antibody Success in Clinic. Nat. Biotech.23, 1073–1078 (2005).
62.
KrauseD. S., Van EttenR. A.Tyrosine Kinases as Targets for Cancer Therapy. N. Engl. J. Med.353, 172–187 (2005).
63.
SagaraN., KatohM.Mitomycin C Resistance Induced by TCF-3 Overexpression in Gastric Cancer Cell Line MKN28 is Associated With DT-diaphorase Down-regulation. Cancer Res.60, 5959–5962 (2000).
64.
ZembutsuH., OhnishiY., TsunodaT.Genome-wide cDNA Microarray Screening to Correlate Gene Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to Anticancer Drugs. Cancer Res.62, 518–527 (2002).
65.
StamR. W., den BoerM. L., MeijerinkJ. P.Differential mRNA Expression of Ara-C-metabolizing Enzymes Explains Ara-C Sensitivity in MLL Gene-rearranged Infant Acute Lymphoblastic Leukemia. Blood101, 1270–1276 (2003).
66.
BubendorfL., KolmerM., KononenJ.Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays. J. Natl. Cancer Inst.91, 1758–1764 (1999).
67.
MoussesS., WagnerU., ChenY.Failure of Hormone Therapy in Prostate Cancer Involves Systematic Restoration of Androgen Responsive Genes and Activation of Rapamycin Sensitive Signaling. Oncogene20, 6718–6723 (2001).
68.
ChenC. D., WelsbieD. S., TranC.Molecular Determinants of Resistance to Antiandrogen Therapy. Nat. Med.10, 33–39 (2004).
69.
GruvbergerS., RingnerM., ChenY.Estrogen Receptor Status in Breast Cancer is Associated with Remarkably Distinct Gene Expression Patterns. Cancer Res.61, 5979–5984 (2001).
70.
SorlieT., PerouC. M., TibshiraniR.Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications. Proc. Natl. Acad. Sci. USA98, 10869–10874 (2001).
71.
KakiuchiS., DaigoY., IshikawaN.Prediction of Sensitivity of Advanced Non-small Cell Lung Cancers to Gefitinib (Iressa, ZD1839). Hum. Mol. Genet.13, 3029–3043 (2004).
72.
TsurutaniJ., WestK. A., SayyahJ., GillsJ. J., DennisP. A.Inhibition of the Phosphatidylinositol 3-kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy. Cancer Res.65, 8423–8432 (2005).
73.
WilkinsonG. R.Drug Metabolism and Variability Among Patients in Drug Response. N. Engl. J. Med.352, 2211–2221 (2005).
74.
NeedA. C., MotulskyA. G., GoldsteinD. B.Priorities and Standards in Pharmacogenetic Research. Nat. Genet.37, 671–681 (2005).
